ClinicalTrials.Veeva
Menu

Find clinical trials for Asthma in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Pulmonary Eosinophilia
Chronic Obstructive Pulmonary Disease
Obstructive Lung Diseases
Allergic Rhinitis
Nasal Polyps
Rhinitis
Lung Diseases

Asthma trials near Paris, Île-de-France, FRA:

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)

in patients ≥ 6 to \< 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations ...

Enrolling
Asthma
Drug: Placebo
Drug: Benralizumab

Phase 3

AstraZeneca
AstraZeneca

Paris, France and 83 other locations

This is a study designed to evaluate efficacy and safety of Tezepelumab in reducing oral corticosteroid use in adult patients with severe asthma...

Active, not recruiting
Asthma
Biological: Tezepelumab

Phase 3

AstraZeneca
AstraZeneca

Antony, France and 76 other locations

To assess the efficacy and safety of tezepelumab in pediatric participants with severe uncontrolled asthma on medium to high-dose inhaled co...

Enrolling
Asthma
Biological: Tezepelumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Paris, France and 100 other locations

The main objective of this study is to evaluate efficacy and safety of patient's learning in self-taking of prescribed asthma maintenance tr...

Active, not recruiting
Asthma in Children
Device: JOE
Ludocare

Paris, France and 12 other locations

BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma...

Enrolling
Asthma
Drug: AZD4604
Other: Placebo

Phase 2

AstraZeneca
AstraZeneca

Antony, France and 152 other locations

of clinically significant exacerbations in participants with severe asthma with an eosinophilic phenotype. Throughout the study, all partici...

Enrolling
Asthma
Biological: Placebo
Biological: Mepolizumab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Paris, France and 429 other locations

treatments in patients undergoing pulmonary care for asthma and/or COPD, who are receiving treatment with Innovair® or Trimbow®. These two ...

Enrolling
Asthma COPD
Device: Hephaï
Hephai

Paris, France and 4 other locations

Asthma is a common pathology, with a prevalence of 6 to 8% and more than 4 million patients in France. Its management is based on different ...

Enrolling
Asthma
Drug: Auto-injector pen, mepolizumab 100 mg/month
Drug: Pre-filled syringe, mepolizumab 100 mg/month

Phase 4

Civil Hospices of Lyon
Civil Hospices of Lyon

Paris, France and 7 other locations

Locations recently updated

inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged \>=18 years with asthma...

Enrolling
Asthma
Drug: Salbutamol HFA-152a
Drug: Salbutamol HFA-134a

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Créteil Cedex, France and 100 other locations

The objective of the study is to establish the predictive value of early blood gene expression signature of Benralizumab response associated with a s...

Enrolling
Severe Asthma
Asthma; Eosinophilic
Drug: Benralizumab Prefilled Syringe

Phase 4

Nantes University Hospital (NUH)

Paris, France and 19 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems